Back to Authors

Schmitz, Norbert

https://orcid.org/0000-0003-4938-7528

A5002498295 | I22465464

Mayo Clinic

University of Münster

Citations 13

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology

Blood | February 23, 2018 | Volume: 131 | Issue: 18 | Pages: 2060-2064

10.1182/blood-2017-12-820605 | PMID 29475959

Key Points HGBL-DH/TH makes up 8% of de novo DLBCL, with HGBL-DH/TH with BCL2 rearrangement being a GCB phenomenon. Restricting FISH testing to tumors with dual protein expression and GCB subtype results in testing <15% of tumors, but missing ∼35% of HGBL-DH/TH.
The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project

The Oncologist | August 11, 2017 | Volume: 22 | Issue: 12 | Pages: 1415-1418

10.1634/theoncologist.2017-0177 | PMID 28798271

This commentary describes the progress of the SEAL [Surrogate Endpoints for Aggressive Lymphoma] research group and invites collaboration in sharing data to continue building a large database of individual patient data from multiple clinical trials in DLBCL.
PROGNOSTIC FACTORS AND IMPACT OF ETOPOSIDE IN ADULTS WITH SYSTEMIC ALK‐POSITIVE ANAPLASTIC LARGE‐CELL LYMPHOMA: A POOLED ANALYSIS OF SIX STUDIES

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 240-240

10.1002/hon.2438_103